Regeneron/$REGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Regeneron

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Ticker

$REGN
Sector
Primary listing

Employees

15,182

Regeneron Metrics

BasicAdvanced
$58B
14.21
$39.67
0.31
$2.64
0.62%

What the Analysts think about Regeneron

Analyst ratings (Buy, Hold, Sell) for Regeneron stock.

Bulls say / Bears say

Dupixent global net sales increased 22% to $4.34 billion in Q2 2025, surpassing analyst estimates and underscoring robust demand for its immunology franchise. (Reuters)
Regeneron’s oncology segment saw Libtayo sales outpace expectations, reaching $377 million versus a forecast of $338.75 million, highlighting strong growth momentum in skin cancer and NSCLC indications. (Reuters)
The FDA granted accelerated approval for Lynozyfic (linvoseltamab) in relapsed or refractory multiple myeloma, marking Regeneron’s first BCMA×CD3 bispecific approval and bolstering its late-stage oncology pipeline. (Reuters)
U.S. net sales of EYLEA fell 25% year-over-year to $1.15 billion in Q2 2025 amid mounting biosimilar pressure and competition from Roche’s Vabysmo. (Reuters)
The FDA twice declined approval for Regeneron’s odronextamab blood cancer therapy due to manufacturing site inspection issues at Catalent, a setback that also delayed three pending EYLEA HD applications. (Reuters)
Amgen’s biosimilar Pavblu will enter the U.S. market after a court decision lifted an injunction, intensifying competition and pricing pressure on Regeneron’s EYLEA franchise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Regeneron Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Regeneron Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs